feed,title,long_url,short_url
Benzinga,Amgen's Lumakras Cuts Risk Of Progression By 34% In KRAS-Mutated Lung Cancer Patients,https://benzinga.com/general/biotech/22/09/28825876/amgens-lumakras-cuts-risk-of-progression-by-34-in-kras-mutated-lung-cancer-patients,https://bit.ly/3d6vSCF
